{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T15:11:30Z","timestamp":1772464290067,"version":"3.50.1"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_almed-2024-0038_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The prevalence of diabetes mellitus type 2 (DMT2) is increasing exponentially worldwide. DMT2 patients have been found to be at a higher risk for bone fractures than the healthy population. Hence, improving our\u00a0understanding of the impact of antidiabetic drugs on bone metabolism is crucial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_almed-2024-0038_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A descriptive, retrospective study involving 106 patients receiving six groups of antidiabetic drugs: insulin; dipeptidylpeptidase four inhibitors (DPP4i); glucagon-like peptide type 1 receptor agonists (GLP1ra); sulfonylureas; sodium-glucose cotransporter two inhibitors (SGLT2i); and pioglitazone, in which osteocalcin (OC), bone alkaline phosphatase (BAP) and C-terminal telopeptide of collagen type 1 or beta-crosslaps (\u03b2-CTx) were determined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_almed-2024-0038_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\u03b2-CTx concentrations were higher in the patients treated with pioglitazone, as compared to patients treated with DPP4i (p=0.035), SGLT2i (p=0.020) or GLP1ra (p&lt;0.001). The lowest \u03b2-CTx concentrations were observed in the patients treated with GLP1ra.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_almed-2024-0038_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Bone remodeling is influenced by the type of antidiabetic drug administered to DMT2 patients. In our study, the patients who received pioglitazone showed higher \u03b2-CTx concentrations, as compared to patients treated with other types of antidiabetic drugs. This finding highlights the\u00a0convenience of avoiding these drugs, especially in postmenopausal women with DMT2. GLP1ra drugs were associated with the lowest \u03b2-CTx concentrations, which suggests that these agents could exert beneficial effects on bone metabolism.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/almed-2024-0038","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T17:50:22Z","timestamp":1712080222000},"page":"85-89","source":"Crossref","is-referenced-by-count":1,"title":["Effects of antidiabetic drugs on bone metabolism"],"prefix":"10.1515","volume":"5","author":[{"given":"Nuria","family":"Padilla Apuntate","sequence":"first","affiliation":[{"name":"Service of Clinical Biochemistry, Miguel Servet University Hospital , Zaragoza , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen G.","family":"Puerto Cabeza","sequence":"additional","affiliation":[{"name":"Service of Clinical Biochemistry, Miguel Servet University Hospital , Zaragoza , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-7624","authenticated-orcid":false,"given":"Alba","family":"Gallego Royo","sequence":"additional","affiliation":[{"name":"Service of Preventive Medicine, Miguel Servet University Hospital , Zaragoza , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1732-4883","authenticated-orcid":false,"given":"Nuria","family":"Go\u00f1i Ros","sequence":"additional","affiliation":[{"name":"Service of Clinical Biochemistry, Miguel Servet University Hospital , Zaragoza , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Abad\u00eda Molina","sequence":"additional","affiliation":[{"name":"Service of Clinical Biochemistry, Miguel Servet University Hospital , Zaragoza , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Acha P\u00e9rez","sequence":"additional","affiliation":[{"name":"Service of Endocrinology and Nutrition, Miguel Servet University Hospital , Zaragoza , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Calmarza","sequence":"additional","affiliation":[{"name":"Service of Clinical Biochemistry, Miguel Servet University Hospital , Zaragoza , Spain"},{"name":"Institute of Biomedical Research (IIS) of Arag\u00f3n , Zaragoza , Spain"},{"name":"University of Zaragoza , Zaragoza , Spain"},{"name":"Spanish Network-Center for Cardiovascular Biomedical Research) (CIBERCV), Carlos III Health Institute , Madrid , Spain"},{"name":"Member of SEQCML Oxidative Stress Commission and Lipoproteins and Vascular Diseases Commission , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"2024041611315839080_j_almed-2024-0038_ref_001","unstructured":"Organizaci\u00f3n Mundial de la Salud. Diabetes. www.who.int. 2021. [citado el 21 de diciembre de 2022]. Disponible en: https:\/\/www.who.int\/es\/news-room\/fact-sheets\/detail\/diabetes."},{"key":"2024041611315839080_j_almed-2024-0038_ref_002","doi-asserted-by":"crossref","unstructured":"Compston, J. Type 2 diabetes mellitus and bone. J Intern Med 2018;283:140\u201353. https:\/\/doi.org\/10.1111\/joim.12725.","DOI":"10.1111\/joim.12725"},{"key":"2024041611315839080_j_almed-2024-0038_ref_003","doi-asserted-by":"crossref","unstructured":"Poiana, C, Capatina, C. Osteoporosis and fracture risk in patients with type 2 diabetes mellitus. Acta Endocrinol 2019;15:231\u20136. https:\/\/doi.org\/10.4183\/aeb.2019.231.","DOI":"10.4183\/aeb.2019.231"},{"key":"2024041611315839080_j_almed-2024-0038_ref_004","doi-asserted-by":"crossref","unstructured":"Rathinavelu, S, Guidry-Elizondo, C, Banu, J. Molecular modulation of osteoblasts and osteoclasts in type 2 diabetes. J Diabetes Res 2018;2018:6354787. https:\/\/doi.org\/10.1155\/2018\/6354787.","DOI":"10.1155\/2018\/6354787"},{"key":"2024041611315839080_j_almed-2024-0038_ref_005","doi-asserted-by":"crossref","unstructured":"Eller-Vainicher, C, Cairoli, E, Grassi, G, Grassi, F, Catalano, A, Merlotti, D, et al.. Pathophysiology and management of type 2 diabetes mellitus bone fragility. J Diabetes Res 2020;2020:7608964. https:\/\/doi.org\/10.1155\/2020\/7608964.","DOI":"10.1155\/2020\/7608964"},{"key":"2024041611315839080_j_almed-2024-0038_ref_006","doi-asserted-by":"crossref","unstructured":"Huang, HY, Huang, ZQ, Hua, LY, Liu, WS, Xu, F, Ge, XQ, et al.. The association between normal serum sodium levels and bone turnover\u00a0in patients with type 2 diabetes. Front Endocrinol 2022;13:927223. https:\/\/doi.org\/10.3389\/fendo.2022.927223.","DOI":"10.3389\/fendo.2022.927223"},{"key":"2024041611315839080_j_almed-2024-0038_ref_007","doi-asserted-by":"crossref","unstructured":"Starup-Linde, J, Eriksen, SA, Lykkeboe, S, Handberg, A, Vestergaard, P. Biochemical markers of bone turnover in diabetes patients--a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int 2014;25:1697\u2013708. https:\/\/doi.org\/10.1007\/s00198-014-2676-7.","DOI":"10.1007\/s00198-014-2676-7"},{"key":"2024041611315839080_j_almed-2024-0038_ref_008","doi-asserted-by":"crossref","unstructured":"Hygum, K, Starup-Linde, J, Harsl\u00f8f, T, Vestergaard, P, Langdahl, BL. Mechanisms in endocrinology: diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. Eur J Endocrinol 2017;176:137\u201357. https:\/\/doi.org\/10.1530\/eje-16-0652.","DOI":"10.1530\/EJE-16-0652"},{"key":"2024041611315839080_j_almed-2024-0038_ref_009","doi-asserted-by":"crossref","unstructured":"Shetty, S, Kapoor, N, Bondu, JD, Thomas, N, Paul, TV. Bone turnover markers: emerging tool in the management of osteoporosis. Indian J\u00a0Endocrinol Metab 2016;20:846\u201352. https:\/\/doi.org\/10.4103\/2230-8210.192914.","DOI":"10.4103\/2230-8210.192914"},{"key":"2024041611315839080_j_almed-2024-0038_ref_010","doi-asserted-by":"crossref","unstructured":"Gilbert, MP, Pratley, RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev 2015;36:194\u2013213. https:\/\/doi.org\/10.1210\/er.2012-1042.","DOI":"10.1210\/er.2012-1042"},{"key":"2024041611315839080_j_almed-2024-0038_ref_011","doi-asserted-by":"crossref","unstructured":"McCarthy, AD, Cortizo, AM, Sedlinsky, C. Metformin revisited: does this regulator of AMP-activated proteinkinase secondarily affect bone metabolism and prevent diabetic osteopathy. World J Diabetes 2016;7:122\u201333. https:\/\/doi.org\/10.4239\/wjd.v7.i6.122.","DOI":"10.4239\/wjd.v7.i6.122"},{"key":"2024041611315839080_j_almed-2024-0038_ref_012","doi-asserted-by":"crossref","unstructured":"Thrailkill, KM, Lumpkin, CKJ, Bunn, RC, Kemp, SF, Fowlkes, JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J\u00a0Physiol Endocrinol Metab 2005;289:735\u201345. https:\/\/doi.org\/10.1152\/ajpendo.00159.2005.","DOI":"10.1152\/ajpendo.00159.2005"},{"key":"2024041611315839080_j_almed-2024-0038_ref_013","doi-asserted-by":"crossref","unstructured":"Conte, C, Epstein, S, Napoli, N. Insulin resistance and bone: a biological partnership. Acta Diabetol 2018;55:305\u201314. https:\/\/doi.org\/10.1007\/s00592-018-1101-7.","DOI":"10.1007\/s00592-018-1101-7"},{"key":"2024041611315839080_j_almed-2024-0038_ref_014","doi-asserted-by":"crossref","unstructured":"Ivaska, KK, Heli\u00f6vaara, MK, Ebeling, P, Bucci, M, Huovinen, V, V\u00e4\u00e4n\u00e4nen, HK, et al.. The effects of acute hyperinsulinemia on bone metabolism. Endocr Connect 2015;4:155\u201362. https:\/\/doi.org\/10.1530\/ec-15-0022.","DOI":"10.1530\/EC-15-0022"},{"key":"2024041611315839080_j_almed-2024-0038_ref_015","doi-asserted-by":"crossref","unstructured":"Kanazawa, I, Yamaguchi, T, Yamamoto, M, Yamauchi, M, Kurioka, S, Yano, S, et al.. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009;94:45\u20139. https:\/\/doi.org\/10.1210\/jc.2008-1455.","DOI":"10.1210\/jc.2008-1455"},{"key":"2024041611315839080_j_almed-2024-0038_ref_016","doi-asserted-by":"crossref","unstructured":"Napoli, N, Chandran, M, Pierroz, DD, Abrahamsen, B, Schwartz, AV, Ferrari, SL, et al.. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol 2017;13:208\u201319. https:\/\/doi.org\/10.1038\/nrendo.2016.153.","DOI":"10.1038\/nrendo.2016.153"},{"key":"2024041611315839080_j_almed-2024-0038_ref_017","doi-asserted-by":"crossref","unstructured":"Hidayat, K, Du, X, Wu, MJ, Shi, BM. The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: systematic review and meta-analysis of observational studies. Obes Rev 2019;20:1494\u2013503. https:\/\/doi.org\/10.1111\/obr.12885.","DOI":"10.1111\/obr.12885"},{"key":"2024041611315839080_j_almed-2024-0038_ref_018","doi-asserted-by":"crossref","unstructured":"Yang, Q, Fu, B, Luo, D, Wang, H, Cao, H, Chen, X, et al.. The multiple biological functions of dipeptidyl peptidase-4 in bone metabolism. Front Endocrinol 2022;13:856954. https:\/\/doi.org\/10.3389\/fendo.2022.856954.","DOI":"10.3389\/fendo.2022.856954"},{"key":"2024041611315839080_j_almed-2024-0038_ref_019","doi-asserted-by":"crossref","unstructured":"Kanda, J, Furukawa, M, Izumo, N, Shimakura, T, Yamamoto, N, Takahashi, HE, et al.. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice. Drug Discov Ther 2020;14:218\u201325. https:\/\/doi.org\/10.5582\/ddt.2020.03073.","DOI":"10.5582\/ddt.2020.03073"},{"key":"2024041611315839080_j_almed-2024-0038_ref_020","doi-asserted-by":"crossref","unstructured":"Abdi, AM, Pasiou, E, Konstantopoulos, P, Driva, TS, Kontos, A, Papagianni, E, et al.. Effects of incretin pathway elements on bone properties. Cureus 2023;15:e33656. https:\/\/doi.org\/10.7759\/cureus.33656.","DOI":"10.7759\/cureus.33656"},{"key":"2024041611315839080_j_almed-2024-0038_ref_021","doi-asserted-by":"crossref","unstructured":"Dong, B, Lv, R, Wang, J, Che, L, Wang, Z, Huai, Z, et al.. The extraglycemic effect of SGLT-2 is on mineral and bone metabolism and bone fracture. Front Endocrinol 2022;13:918350. https:\/\/doi.org\/10.3389\/fendo.2022.918350.","DOI":"10.3389\/fendo.2022.918350"},{"key":"2024041611315839080_j_almed-2024-0038_ref_022","doi-asserted-by":"crossref","unstructured":"Jackuliak, P, Ku\u017ema, M, Payer, J. Effect of antidiabetic treatment on bone. Physiol Res 2019;68:107\u201320. https:\/\/doi.org\/10.33549\/physiolres.934297.","DOI":"10.33549\/physiolres.934297"},{"key":"2024041611315839080_j_almed-2024-0038_ref_023","doi-asserted-by":"crossref","unstructured":"Tang, HL, Li, DD, Zhang, JJ, Hsu, YH, Wang, TS, Zhai, SD, et al.. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 2016;18:1199\u2013120. https:\/\/doi.org\/10.1111\/dom.12742.","DOI":"10.1111\/dom.12742"},{"key":"2024041611315839080_j_almed-2024-0038_ref_024","doi-asserted-by":"crossref","unstructured":"Mori, H, Okada, Y, Tanaka, Y. The effects of pioglitazone on bone formation and resorption markers in type 2 diabetes mellitus. Intern Med 2017;56:1301\u20136. https:\/\/doi.org\/10.2169\/internalmedicine.56.8096.","DOI":"10.2169\/internalmedicine.56.8096"},{"key":"2024041611315839080_j_almed-2024-0038_ref_025","doi-asserted-by":"crossref","unstructured":"Xiao, WH, Wang, YR, Hou, WF, Xie, C, Wang, HN, Hong, TP, et al.. The effects of pioglitazone on biochemical markers of bone turnover in the patients with type 2 diabetes. Int J Endocrinol 2013;2013:290734. https:\/\/doi.org\/10.1155\/2013\/290734.","DOI":"10.1155\/2013\/290734"}],"container-title":["Advances in Laboratory Medicine \/ Avances en Medicina de Laboratorio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2024-0038\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2024-0038\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:43:22Z","timestamp":1713282202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2024-0038\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]},"published-print":{"date-parts":[[2024,4,16]]}},"alternative-id":["10.1515\/almed-2024-0038"],"URL":"https:\/\/doi.org\/10.1515\/almed-2024-0038","relation":{},"ISSN":["2628-491X"],"issn-type":[{"value":"2628-491X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}